Clinical trials: Primary Antiphospholipid Syndrome
Primary Antiphospholipid Syndrome
Ocular Findings in Women With Primary Antiphospholipid Syndrome
Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic thrombosis and bad obstetric history. APS secondary to another medical disorder is the most common. Visual and ocular changes e.g.
- Trial name
- NCT03459508
- Testing
- Ophthalmological examination
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients…
- Conditions
- Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07085676
- Testing
- HBI0101 CART
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Polina Stepensky
Antiphospholipid Syndrome in Pregnancy, Anticoagulants
HYDROxychloroquine in Syndrome Primary AntiPhospholipid
Antiphospholipid syndrome (APS) is defined by thrombosis or obstetric complication (≥ 3 spontaneous miscarriages or fetal death or prematurity <34 weeks gestation-related amenorrhea (SA)) associated with antiphospholipid…
- Trial name
- HYDROSAPL (NCT04275778)
- Testing
- Plaquenil 200Mg Tablet
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antiphospholipid Syndrome (APS)
Effect of Belimumab on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.
- Trial name
- NCT06747312
- Testing
- Belimumab+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Primary Antiphospholipid Syndrome
The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study
This study is an Investigator initiated, randomized, multicenter, double-blind, placebo-control study. The aim of this study is to evaluate the safety and efficiency of Sirolimus for primaty antiphospholipid syndrome patients at…
- Trial name
- NCT06504420
- Testing
- Sirolimus
- Volunteers
- 70 people
- Sponsor
- Peking University People's Hospital
Antiphospholipid Syndrome
Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome
Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course.
- Trial name
- NCT07142239
- Testing
- • Complete blood count , MPV, Calculation of PLR: Platelet count / Lymphocyte count and Calculation of NLR:, Antiphospholipid antibody profile
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- New Valley University
Anti Phospholipid Syndrome
Telitacicept in Primary APS Patients
This is a single-arm pilot study in Peking Union Medical College Hospital. Telitacicept will be added on traditional antithrombotic and immunosuppressive treatment in primary antiphospholipid syndrome (APS) patients with three…
- Trial name
- NCT05078710
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Preeclampsia, Immunologic Disease
Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome
The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.
- Conditions
- Preeclampsia, Immunologic Disease, Antiphospholipid Antibody Syndrome Primary, Pregnancy Complications
- Trial name
- NCT05786235
- Testing
- Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Autoimmune Disorders
Daratumumab in Primary Antiphospholipid Syndrome
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS).
- Trial name
- DARE-APS (NCT05671757)
- Testing
- Daratumumab
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus, Systemic Scleroderma
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase.
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome
- Trial name
- AutoB-Tetramer (NCT07251179)
- Testing
- blood draw
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Antiphospholipid Syndrome
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
- Trial name
- NCT01784523
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid Syndrome (APS)
Effect of Telitacicept on Antibody Titers in Primary APS Patients
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
- Trial name
- NCT06315530
- Testing
- Telitacicept+SOC, SOC
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome
Omega 3 in LES and APS
It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy.
- Trial name
- NCT01956188
- Testing
- EPA and DHA supplementation
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- University of Sao Paulo
Antiphospholipid Syndrome
Clinical Outcomes of Primary Versus Secondary Antiphospholipid Syndrome
Observational retrospective cohort study to assess clinical outcomes in patients with primary versus secondary antiphospholipid syndrome
- Trial name
- NCT06808607
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Assiut University
Primary Antiphospholipid Syndrome
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) combines thrombotic (venous and/or arterial) and/or obstetrical manifestations, along with biological anomalies related to the presence of antiphospholipid antibodies.
- Trial name
- PAPIRUS (NCT03540810)
- Testing
- Hydroxychloroquine
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Angers
Antiphospholipid Syndrome
Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome
This is an interventional drug study designed as a pilot for a randomized clinical trial, aimed at assessing the effect of hydroxychloroquine on the incidence rate of thrombosis in patients with primary antiphospholipid syndrome…
- Trial name
- NCT04153201
- Testing
- Hydroxychloroquine
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- National and Kapodistrian University of Athens
Antiphospholipid Syndrome (APS)
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
This is a phase II, single-centre, open-label pilot study evaluating the safety and tolerability of anifrolumab in adult patients with primary antiphospholipid syndrome (APS).
- Trial name
- AnifAPS (NCT07584083)
- Testing
- Anifrolumab
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- National and Kapodistrian University of Athens
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Antiphospholipid Syndrome
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator, plays a pivotal role in regulation of fibrinolysis in vitro and in vivo and has been identified as a new autoantigen in…
- Trial name
- MONOCYTAN (NCT06373926)
- Testing
- blood withdrawal
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic